SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Arthur Radley who wrote (10665)11/3/1997 9:47:00 AM
From: Henry Niman  Read Replies (1) of 32384
 
TD, I don't have enough details. Rezulin is a first generation TZD and is taken at high doses (200 mg to 600 mg). Drugs at high concentrations can cause liver problems. SBH's TZD is taken at about 1/10 of the concentration (and I suspect that Takeda's second generation compound is also used at lower levels). Targretin has been shown to synergize with SBH's and Takeda's TZD and of course LGND has their own TZD program. One of the benefits of synergization is the ability to use each component at a lower level, so the Rezulin problems may be a plus for LGND (diabetics without the complications love Rezulin).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News